<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Miller SL</submitter><funding>Cerebral Palsy Alliance Research Foundation</funding><funding>National Health and Medical Research Council</funding><pagination>1066-1079</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC9828769</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>92(6)</volume><pubmed_abstract>&lt;h4>Objective&lt;/h4>Seizures are more common in the neonatal period than at any other stage of life. Phenobarbital is the first-line treatment for neonatal seizures and is at best effective in approximately 50% of babies, but may contribute to neuronal injury. Here, we assessed the efficacy of phenobarbital versus the synthetic neurosteroid, ganaxolone, to moderate seizure activity and neuropathology in neonatal lambs exposed to perinatal asphyxia.&lt;h4>Methods&lt;/h4>Asphyxia was induced via umbilical cord occlusion in term lambs at birth. Lambs were treated with ganaxolone (5mg/kg/bolus then 5mg/kg/day for 2 days) or phenobarbital (20mg/kg/bolus then 5mg/kg/day for 2 days) at 6 hours. Abnormal brain activity was classified as stereotypic evolving (SE) seizures, epileptiform discharges (EDs), an</pubmed_abstract><journal>Annals of neurology</journal><pubmed_title>Ganaxolone versus Phenobarbital for Neonatal Seizure Management.</pubmed_title><pmcid>PMC9828769</pmcid><funding_grant_id>PG15417</funding_grant_id><funding_grant_id>APP1144414</funding_grant_id><pubmed_authors>Allison BJ</pubmed_authors><pubmed_authors>Nitsos I</pubmed_authors><pubmed_authors>Malhotra A</pubmed_authors><pubmed_authors>Bennet L</pubmed_authors><pubmed_authors>Boyd BJ</pubmed_authors><pubmed_authors>Miller SL</pubmed_authors><pubmed_authors>Jenkin G</pubmed_authors><pubmed_authors>Wong F</pubmed_authors><pubmed_authors>Walker DW</pubmed_authors><pubmed_authors>Yawno T</pubmed_authors><pubmed_authors>Castillo-Melendez M</pubmed_authors><pubmed_authors>Pham Y</pubmed_authors><pubmed_authors>Mihelakis J</pubmed_authors><pubmed_authors>Fahey MC</pubmed_authors><pubmed_authors>Hunt RW</pubmed_authors><pubmed_authors>Hirst JJ</pubmed_authors><pubmed_authors>Sutherland AE</pubmed_authors><pubmed_authors>McDonald C</pubmed_authors></additional><is_claimable>false</is_claimable><name>Ganaxolone versus Phenobarbital for Neonatal Seizure Management.</name><description>&lt;h4>Objective&lt;/h4>Seizures are more common in the neonatal period than at any other stage of life. Phenobarbital is the first-line treatment for neonatal seizures and is at best effective in approximately 50% of babies, but may contribute to neuronal injury. Here, we assessed the efficacy of phenobarbital versus the synthetic neurosteroid, ganaxolone, to moderate seizure activity and neuropathology in neonatal lambs exposed to perinatal asphyxia.&lt;h4>Methods&lt;/h4>Asphyxia was induced via umbilical cord occlusion in term lambs at birth. Lambs were treated with ganaxolone (5mg/kg/bolus then 5mg/kg/day for 2 days) or phenobarbital (20mg/kg/bolus then 5mg/kg/day for 2 days) at 6 hours. Abnormal brain activity was classified as stereotypic evolving (SE) seizures, epileptiform discharges (EDs), an</description><dates><release>2022-01-01T00:00:00Z</release><publication>2022 Dec</publication><modification>2026-03-17T15:46:10.129Z</modification><creation>2025-04-19T23:08:17.338Z</creation></dates><accession>S-EPMC9828769</accession><cross_references><pubmed>36054160</pubmed><doi>10.1002/ana.26493</doi></cross_references></HashMap>